Modified Dendritic Cells Induce Immune Response

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 10
Volume 8
Issue 10

PITTSBURGH-University of Pittsburgh researchers have shown that immature dendritic cells can be genetically modified to serve as an effective vehicle for presenting tumor antigens to the immune system. Such cells were shown to induce a significant and therapeutic tumor-specific immune response in an animal model.

PITTSBURGH—University of Pittsburgh researchers have shown that immature dendritic cells can be genetically modified to serve as an effective vehicle for presenting tumor antigens to the immune system. Such cells were shown to induce a significant and therapeutic tumor-specific immune response in an animal model.

The finding resulted from a two-step investigation, Hideaki Tahara, MD, PhD, assistant professor of surgery, reported at the 90th annual meeting of the American Association for Cancer Research (AACR) in Philadelphia.

First, the dendritic cells, a type of antigen-presenting cell, were injected directly into tumor tissue in mice. Then, Dr. Tahara and his colleagues studied the animals’ spleen and lymph nodes to measure the systemic immune response.

They found that the injected dendritic cells were able to process the tumor antigens at the tumor site, migrate to the lymph nodes, and present the antigens to the lymphoid cells, which released significant quantities of interferon-gamma, an immunostimulatory substance. “Interferon-gamma levels were significantly higher in these mice than in animals that received saline,” Dr. Tahara said.

In the second step, Dr. Tahara’s group genetically modified immature dendritic cells to secrete the tumor-fighting and immunostimulatory substance interleu-kin-12 (IL-12), and injected the cells directly into tumor tissue. The secretion of IL-12 by the genetically modified dendritic cells was found to further enhance the immune system’s response to the tumor.

“We have developed a system that is able to effectively present the tumor as a foreign agent to the immune system and simultaneously activate the immune system’s response to the tumor,” Dr. Tahara said, “and we are now moving forward with studying this system in cancer patients.”

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
Management of adverse effects and access to cellular therapies among community oncologists represented key points of discussion in multiple myeloma.
2 experts are featured in this series.
2 experts are featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Related Content